Royal Bank of Canada Reaffirms Sector Perform Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “sector perform” rating reissued by equities research analysts at Royal Bank of Canada in a research report issued to clients and investors on Monday, Marketbeat reports. They currently have a $3.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $24.00. Royal Bank of Canada’s target price would indicate a potential upside of 120.59% from the company’s current price.

Several other brokerages have also weighed in on MRNS. Oppenheimer reaffirmed a “market perform” rating and issued a $9.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, March 26th. Finally, StockNews.com downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Marinus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $18.21.

Marinus Pharmaceuticals Stock Down 81.9 %

Shares of MRNS traded down $6.16 during trading hours on Monday, reaching $1.36. The company’s stock had a trading volume of 23,848,040 shares, compared to its average volume of 762,655. The company has a quick ratio of 4.01, a current ratio of 4.07 and a debt-to-equity ratio of 5.68. The firm has a market cap of $74.70 million, a price-to-earnings ratio of -0.54 and a beta of 0.91. The company has a 50 day moving average of $9.24 and a two-hundred day moving average of $8.60. Marinus Pharmaceuticals has a 1-year low of $1.35 and a 1-year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The company had revenue of $7.19 million during the quarter, compared to analysts’ expectations of $7.78 million. During the same quarter in the previous year, the company earned ($0.76) EPS. As a group, research analysts predict that Marinus Pharmaceuticals will post -2.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. FMR LLC increased its holdings in shares of Marinus Pharmaceuticals by 1,887.9% during the 1st quarter. FMR LLC now owns 4,433 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 4,210 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in Marinus Pharmaceuticals in the 3rd quarter valued at approximately $38,000. Quantbot Technologies LP acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $40,000. Ameritas Investment Partners Inc. acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at approximately $45,000. Finally, Jane Street Group LLC acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at approximately $47,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.